Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cystic fibrosis - Care at Mayo Clinic - Mayo Clinic

Cystic fibrosis care at Mayo Clinic Your Mayo Clinic care team Discussing care Mayo Clinic specialists work together to decide the best treatment approach. Mayo Clinic doctors in a wide array of specialties work together as a multispecialty team to give coordi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cystic fibrosis care at Mayo Clinic

Your Mayo Clinic care team

Mayo Clinic specialists work together to decide the best treatment approach. Mayo Clinic doctors in a wide array of specialties work together as a multispecialty team to give coordinated, comprehensive care. Pulmonary Medicine offers the Mayo Clinic Cystic Fibrosis Center, which is certified by the Cystic Fibrosis Foundation as a cystic fibrosis care center. The clinic specializes in the care of pediatric and adult patients. Doctors trained in lung conditions, known as pulmonologists, work with medical professionals in many areas to give you personalized, top-quality care. The dedicated staff includes physicians, nurses, dietitians, genetic counselors, physical therapists, social workers and respiratory therapists. The center staff works closely with the Transplant Center . Together they've done successful transplants in many people with advanced cystic fibrosis lung disease. This team approach often allows doctors to evaluate your condition and develop a treatment plan within a few days.

Advanced diagnosis and treatment

Experts at Mayo Clinic's campuses in Minnesota and Florida offer the latest in diagnosis and treatment of cystic fibrosis. A trained, multispecialty team of experienced doctors and other medical professionals evaluate and treat people who have CF. Mayo Clinic's Pulmonary Rehabilitation Program helps people who have long-term pulmonary disease. Mayo Clinic offers pulmonary rehabilitation programs for people with CF. The specialists in this program work with you to help you manage your symptoms and improve how well you do daily. Mayo Clinic doctors may recommend a lung transplant for adults with CF who meet specific criteria. Your doctor may discuss this with you if you're a candidate for a lung transplant. Mayo Clinic's Lung Transplant Program provides comprehensive care for people after lung transplantation.

Discussing the lung transplant process

A Mayo Clinic lung transplant doctor explains the transplant process and the comprehensive care approach.

If your child has cystic fibrosis

As part of the Mayo Clinic Children's Center, highly skilled experts in Pediatric Pulmonology assess, diagnose and treat infants, children and teenagers who have cystic fibrosis. This comprehensive healthcare team delivers personalized, effective treatment for your child in a family-friendly way. Medical professionals from various specialties work together with one another and then talk with you to set goals and develop a customized evaluation and treatment plan for your child. At the Mayo Clinic Children's Center, pediatric experts focus on one child and family at a time, believing that the needs of their patients come first. They treat each child and family with warmth, compassion and respect.

Vest therapy for cystic fibrosis

A Mayo Clinic respiratory therapist explains the purpose of vest therapy to a child with cystic fibrosis and his mother.

Personal approach

Doctors at Mayo Clinic provide care for you as a whole person. They take the time to get to know you and work with you to provide exactly the care you need. The healthcare team will discuss your condition with you and develop an appropriate treatment plan for you.

Research

Doctors at Mayo Clinic study genetics, diagnostic tests and treatments for cystic fibrosis and are actively involved in CF clinical trials.

Expertise and rankings

Expertise and experience

Mayo Clinic specialists have outstanding training and expertise with many years of experience in evaluating and treating adults and children with cystic fibrosis. Each year experts at Mayo Clinic evaluate and treat more than 200 people who have cystic fibrosis.

Transplant expertise

Experts in Mayo Clinic's Transplant Center have extensive expertise and experience in evaluating and treating adults with cystic fibrosis or other conditions who may need lung transplants. Highly skilled surgeons do lung transplant surgery.

Locations, travel and lodging

Mayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states. For more information on visiting Mayo Clinic, choose your location below:

Costs and insurance

Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people. In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need. Learn more about appointments at Mayo Clinic . Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card.

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, have been recognized among the top Pulmonology hospitals in the nation by U.S. News & World Report. Learn more about this top honor

Cystic fibrosis

  • Symptoms & causes
  • Diagnosis & treatment
  • Doctors & departments
  • Care at Mayo Clinic
  • Diseases & Conditions
  • Cystic fibrosis

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What is cystic fibrosis? A Mayo Clinic expert explains

Learn more from pulmonologist Sarah Chalmers, M.D. Cystic fibrosis (CF) is a condition passed down in families that causes damage to the lungs, digestive system and other organs in the body. CF affects the cells that make mucus, sweat and digestive juices. These fluids, also called secretions, are usually thin and slippery to protect the body's internal tubes and ducts and make them smooth pathways. But in people with CF, a changed gene causes the secretions to become sticky and thick. The secretions plug up pathways, especially in the lungs and pancreas. CF gets worse over time and needs daily care, but people with CF usually can attend school and work. They often have a better quality of life than people with CF had in past decades. Better screening and treatments mean that people with CF now may live into their mid- to late 50s or longer, and some are being diagnosed later in life.

Source: www.mayoclinic.org ↗
02What Is Cystic Fibrosis?

Cystic fibrosis (CF) is a genetic disorder, which means you get it from your parents at birth. It affects your lungs, pancreas, and other organs. CF changes the way chloride (salt) moves through the cells of your body. This causes the mucus (which should be thin and slippery) in various organs to become thick and sticky. Over time, this thick mucus builds up inside your airways, making it hard to breathe. The mucus traps germs and leads to infections and inflammation. It can also cause severe, long-term damage to the lungs and lead to respiratory failure (inability to breathe normally) and death. In the pancreas, the thick mucus caused by CF prevents the release of digestive enzymes when you eat. This leads to malnutrition and poor growth. CF can also cause liver disease, reproductive problems, and cystic fibrosis-related diabetes (CFRD). More than 40,000 people in the U.S. live with CF. Doctors diagnose about 1,000 new cases each year. Today, more than half of the CF population is aged 18 or older, and new treatments have expanded the life expectancy by decades.

Source: www.webmd.com ↗
03What to expect from your doctor

After getting detailed information about the symptoms and your family's medical history, your healthcare professional may order tests to help with diagnosis and plan treatment. Your healthcare professional also may ask questions, such as: What symptoms are you or your child having? When did the symptoms start? Does anything make the symptoms better or worse? Has anyone in your family ever had cystic fibrosis? Has growth been average and weight been stable? Cystic fibrosis. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/cystic-fibrosis. Accessed Aug. 8, 2024. Bronchiectasis. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/bronchiectasis. Accessed Aug. 8, 2024. FAQs: Cystic fibrosis: Prenatal screening and diagnosis. American College of Obstetricians and Gynecologists. https://www.acog.org/womens-health/faqs/cystic-fibrosis-prenatal-screening-and-diagnosis. Accessed Aug. 8, 2024. Ferri FF. Cystic fibrosis. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Kliegman RM, et al., eds. Cystic fibrosis. In: Nelson Textbook of Pediatrics. 22nd ed. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Kellerman RD, et al. Cystic fibrosis. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Lockwood CJ, et al., eds. Respiratory diseases in pregnancy. In: Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. 9th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Ong T, et al. Cystic fibrosis: A review. JAMA. 2023; doi:10.1001/jama.2023.8120. Rubin R. Tackling the misconception that cystic fibrosis is a "white people's disease." JAMA. 2021; doi:10.1001/jama.2021.5086. Care centers. Cystic Fibrosis Foundation. https://www.cff.org/managing-cf/care-centers. Accessed Aug. 8, 2024. Trikafta (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.trikafta.com/. Accessed Aug. 8, 2024. Symdeko (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.symdeko.com/. Accessed Aug. 8, 2024. Orkambi (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.orkambi.com/. Accessed Aug. 8, 2024. Kalydeco (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.kalydeco.com/. Accessed Aug. 8, 2024. Pilewski JM. Update on lung transplantation for cystic fibrosis. Clinics in Chest Medicine. 2022; doi:10.1016/j.ccm.2022.07.002. Fridell JA, et al. Pancreas transplantation for cystic fibrosis: A frequently missed opportunity. Clinical Transplantation. 2021; doi:10.1111/ctr.14371. Wadsworth LE, et al. Non-invasive ventilation is associated with long-term improvements in lung function and gas exchange in cystic fibrosis adults with hypercapnic respiratory failure. Journal of Cystic Fibrosis. 2021; doi:10.1016/j.jcf.2021.05.011. Allscripts EPSi. Mayo Clinic. Medical review (expert opinion). Mayo Clinic. Oct. 18, 2024.

Source: www.mayoclinic.org ↗
04How Was It Studied for the Treatment of Cystic Fibrosis?

The effectiveness and safety of Alyftrek for cystic fibrosis was studied in two randomized trials (Trials VX20-121-102 and VX20-121-103). These studies compared Alyftrek to another standard treatment for cystic fibrosis ( elexacaftor /tezacaftor/ivacaftor). People in the studies first received elexacaftor/tezacaftor/ivacaftor for four weeks, then were assigned to continue this treatment or switch to Alyftrek for 52 weeks. Trial VX20-121-102 included 398 people with F508del-minimal function genotypes. The median (middle) age was 31 and 41% of people were female; most people in the study were White (97%), while 1% were Black or African American, and <1% were Asian. Trial VX20-121-103 included 573 people with F508del-F508del, F508del-residual function, F508del-gating, or other responsive mutations. The median age was 33.1 and 49% of people in the study were female. Most people were White (93%), 1% were Black or African American, and <1% each were Southeast Asian, other Asian, or American Indian/Alaska Native. The study found that Alyftrek was similar to elexacaftor/tezacaftor/ivacaftor in improving lung function (measured by forced expiratory volume in 1 second [FEV1 %]), with similar results seen in both studies. Additionally, Alyftrek led to greater reductions in sweat chloride, a key measure of CFTR function, in both studies. The results of these studies suggest that Alyftrek is a promising alternative to elexacaftor/tezacaftor/ivacaftor, offering similar lung function benefits and helping CFTR to work better. The safety profile of Alyftrek was similar to that of elexacaftor/tezacaftor/ ivacaftor . The most common side effects included worsening lung infections (28%), cough (23%), COVID-19 (22%), and the common cold (nasopharyngitis; 21%). Serious side effects were similar between groups, with 14% of people treated with Alyftrek and 16% of people treated with standard treatment experiencing severe reactions. High liver enzymes were slightly more common in the Alyftrek group, but overall safety findings were similar to those seen in other studies. Your results may differ from what was seen in clinical studies.

Source: www.webmd.com ↗
05Will I need to do anything to prepare for the test?

You don't need any special preparations for a sweat test, but you should avoid applying any creams or lotions to the skin for 24 hours before the test.

Source: medlineplus.gov ↗
Research context

Read sources and limitations before applying a claim.

Research and Statistics: Who Has Cystic Fibrosis?

About 40,000 people are living with cystic fibrosis in the United States, and there are approximately 105,000 people with CF worldwide. (3) More than 75 percent of people with the disease are diagnosed by age 2, and more than half of all people living with cystic fibrosis are 18 or older. CF occurs predominantly in white populations, at a rate of 1 in 2,500 births. Between 2 and 5 percent of white people are carriers of the CFTR gene variant but have no overt clinical signs of disease. The disease is less common among African Americans, occurring at the much lower frequency of approximately 1 out of 17,000 births. (15) CF gene variants are most prevalent in persons of northern and central European ancestries or of Ashkenazi Jewish descent. They are rarely found in Native Americans, Asians, or native Africans. (16) CF is equally common among men and women, but women patients fare significantly worse than male patients with the disease. The median survival age for female CF patients is about three years younger than it is for men, but the reasons for the poorer survival rates among women are not completely understood. (17)

Source: everydayhealth.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →